Biochemistry and Immunology of Poly(ethylene glycol)-Modified Adenosine Deaminase (PEG-ADA)


Journal Article

Poly(ethylene glycol)-modified bovine adenosine deaminase (PEG-ADA) was the first PEGylated protein to undergo clinical trial. It has been effective in correcting the toxic biochemical effects of ADA substrates, and in treating the fatal immune deficiency disease caused by ADA deficiency. The experience gained from monitoring PEG-ADA therapy over the past decade provides unique insight into the immunological response to chronic treatment with a PEGylated enzyme.

Duke Authors

Cited Authors

  • Hershfield, MS

Published Date

  • December 1, 1997

Published In

Volume / Issue

  • 680 /

Start / End Page

  • 145 - 154

International Standard Serial Number (ISSN)

  • 0097-6156

Citation Source

  • Scopus